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Abstract
Systemic Lupus Erythematosus (SLE) is a chronic multisystem autoimmune disease with a 
heterogeneous pattern of clinical and serological manifestations. The predilection for women, 
particularly of childbearing age, combined with improved survival has led to increasing 
numbers of women with lupus considering pregnancy. Management of pregnancy in SLE 
however, requires careful planning and close medical and obstetric monitoring to ensure 
optimal outcomes. This review, discusses possible causes of subfertility, issues regarding 
contraception and family planning as well as management of lupus during pregnancy and 
outcomes in pregnant women with SLE.
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Introduction
Systemic lupus erythematosus (SLE) is a chronic multisystem 
autoimmune disease with a heterogeneous pattern of clinical 
and serological manifestations. Pathogenesis of this disease 
involves a complex interaction between gene susceptibility, 
hormonal influences, and certain environmental triggers 
which induce autoantibody production, formation of immune 
complexes, activation of T‑lymphocytes, dysregulation of 
apoptosis, and production of proinflammatory cytokines.[1] It 
has an overall incidence of 4.9–5.5 and prevalence of 72.8–97 
in recent UK and US population estimates with a 6–10‑fold 
female predominance.[2,3]
The predilection for women, particularly of childbearing 
age, combined with improved survival has led to increasing 
numbers of women with lupus considering pregnancy. 
Management of pregnancy in SLE, however, requires careful 
planning and close medical and obstetric monitoring to 
ensure optimal outcomes. In this review, we shall address 
possible causes of subfertility, issues regarding contraception 
and family planning, as well as management of lupus during 
pregnancy, and outcomes in pregnant women with SLE.
Fertility and Parity may be Reduced in Women 
with Systemic Lupus Erythematosus
Reduced parity has been documented in patients with 
SLE. A study of women with SLE (n = 119) found that 
they viewed their disease as a barrier to childbearing[4] 
and a multicenter study found that 42% of women with 
SLE (n = 339) diagnosed before 50 years of age had never 
been pregnant.[5] The reasons for this reduced parity in SLE 
are complex, and potential causes of infertility have been 
investigated. Interestingly, a higher incidence of SLE (~1%) 
has been identified among infertile women in the general 
population than would be expected given the incidence 
of SLE in adult women.[6] The precise incidence however 
of infertility in SLE is uncertain, and a number of potential 
factors have been identified and are summarized in Table 1.
Age is an important factor in all women as ovarian reserve 
and oocyte quality diminishes over time. Maternal age has 
been steadily increasing in recent years in economically 
developed societies with many women now deferring 
pregnancy until the end of their fourth decade, and this 
phenomenon may be exacerbated in patients with SLE to 
allow for a period of disease remission and drug washout 
preconception.[7]
Menstrual disturbances are common in women with 
lupus and associated with increased disease activity. 
This finding is likely to reflect the adverse effects of any 
active inflammatory disease process on menstruation but 
has also been linked with the production of anticorpus 
luteum antibodies and corresponding high levels of 
follicle stimulating hormone.[8] Drugs used to treat 
Access this article online
Website:
www.indianjrheumatol.com
Quick Response 
Code
DOI:
10.4103/0973-3698.194546
Review Article
Jones and Giles: SLE in pregnancy
Indian Journal of Rheumatology ¦ Supplement 2 2016S129
lupus have also been linked with infertility. In particular, 
cyclophosphamide (CYC) is gonadotoxic and the risk of 
ovarian failure associated with this drug is increased by 
patient age, cumulative CYC dose and with oral compared 
with intermittent intravenous CYC.[9] Other drugs that have 
been linked with infertility include: Cyclooxygenase (COX)‑2 
inhibitors that have been associated with luteinized 
unruptured follicle syndrome, and high‑dose corticosteroids 
have been associated with menstrual disturbances and 
reduced libido.[10] It is important to note, however, 
that while the safety of COX‑2 inhibitors has not been 
established in pregnancy, corticosteroids are routinely used 
to treat SLE in pregnancy.
Patients with chronic renal failure secondary to 
lupus nephritis may develop infertility through 
hypothalamic‑pituitary dysfunction, which manifests 
as a menstrual irregularity and anovulatory cycles. 
Patients with renal failure and those on dialysis tend to 
have raised prolactin which reduces the production of 
gonadotropin‑releasing hormone from the hypothalamus.[10]
Up to 40% of patients with SLE test positive for 
antiphospholipid antibody (aPL) and around half of these 
patients have antiphospholipid syndrome (APS).[11] This 
disease is characterized by the association of vascular 
thromboses and/or various forms of pregnancy morbidity.[12] 
There is an established link between aPL and fetal loss in 
patients with APS, with various studies reporting direct 
effects of aPL on trophoblastic and/or endometrial cells 
that can impair placental implantation and formation, 
reviewed in.[13] A more direct link, however, between aPL 
and infertility remains controversial and assessment for aPL 
is not indicated in women undergoing in vitro fertilization 
on the basis of existing data from prospective studies.[14]
Psychosocial influences are important in fertility. SLE is 
associated with fatigue and depression and subsequent 
loss of libido/sexual function in women.[15] Therefore, an 
apparent reduction in fertility may actually reflect reduced 
frequency of sexual intercourse.
Pregnancy Planning and Contraception
Preconception assessment and counseling are a vital 
component of pregnancy planning in patients with SLE to 
evaluate for specific risks in relation to pregnancy.
Poor pregnancy outcomes in patients with SLE can 
be predicted by the level of lupus disease activity at 
conception and during pregnancy, a history of lupus 
nephritis, the presence of maternal anti‑Ro/La antibodies, 
APS, and maternal hypertension.[16] Patients are encouraged 
to time a pregnancy to begin during a period of disease 
remission. A recent retrospective study of 183 pregnancies 
in 143 patients with SLE has shown that 4 months[17] rather 
than the previously reported 6 months[18] of SLE quiescence 
significantly improved pregnancy outcomes.
Preconception assessment must, therefore, address: 
Disease activity, to ensure conception occurs during 
disease remission; disease burden and presence of organ 
involvement, such as lupus nephritis; the presence of 
aPL and anti‑Ro antibodies; medication regime, to ensure 
avoidance of any drugs that are incompatible with 
pregnancy; and other comorbidities. Advanced recognition 
of these factors will enable the doctor and patient to 
make informed decisions regarding the risk and timing 
of pregnancy with appropriate changes in therapy to 
minimize the chances of an adverse pregnancy outcome.
There are very few absolute contraindications to 
pregnancy in patients with SLE, and these include 
pulmonary hypertension, moderate to severe renal 
impairment, severe restrictive lung disease, advanced 
heart failure, and previous severe hypertensive disorders 
of pregnancy despite therapy.[19] The presence of any of 
these complications should lead to a discussion with the 
patient of the unacceptably high risk to both mother and 
fetus and advice to avoid pregnancy.
Given the potential risk for disease flare and adverse 
pregnancy outcomes in women with SLE, it is important 
that effective contraception is used until a time when 
these women can safely consider pregnancy. It is equally 
important that the appropriate form of contraception is 
selected. Family planning discussions, however, are often 
neglected during routine consultations. A US study found 
that 51 of 86 (59%) women with SLE at risk for unplanned 
pregnancy (defined as premenopausal women <45 years 
of age who were sexually active with men) reported no 
contraceptive counseling in the past year and inconsistent 
contraceptive use, despite frequent use of potentially 
teratogenic medications.[20] Furthermore, the most 
reported use of contraception in this study was barrier 
methods which have a high failure rate.
Small cohort and case studies have shown that 
hormonal contraceptive agents increase the risk of SLE 
disease flares.[21,22] Two large, randomized, clinical trials, 
however, have not identified a significant impact of 
contraceptive agents on SLE disease activity. In particular, 
oral contraceptives did not increase the risk of flares 
in premenopausal women with SLE whose disease was 
stable.[23] Furthermore, disease activity remained mild and 
Table 1: Factors which may contribute to reduced fertility 
in lupus patients
Age ‑ Delays to allow for disease remission and drug washout
Menstrual disturbances ‑ Associated with disease activity
Drugs ‑ Direct effect on ovarian function (CYC)
Renal failure
Antiphospholipid syndrome ‑ Unproven link with infertility
Psychosocial
CYC: Cyclophosphamide
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stable among women with SLE irrespective of whether they 
received combined oral contraceptives, a progestin‑only 
pill or copper intrauterine device.[24] Patients with severe 
disease, however, were excluded from these trials.
An important consideration is the elevated risk of 
thrombosis with estrogen‑containing contraceptives[25] 
making them unsuitable for patients with SLE and 
APS. In patients with SLE who are aPL positive but 
lack APS, a stratification of risk with specialist advice if 
necessary is recommended. In particular, patients with 
persistence of aPL positivity, high titer aPL, presence of 
lupus anticoagulant (LA) positivity, triple positivity for 
anticardiolipin (aCL), anti‑β2glycoprotein I (aβ2GPI), and LA, 
as well as IgG aPL, have a greater risk for future thrombotic 
events[26] and estrogen‑containing contraceptives are best 
avoided in these patients.
The use of an intrauterine contraceptive device is 
a suitable alternative, particularly in patients with 
increased thrombotic risk. Although concomitant 
immunosuppressive therapy, raises theoretical concerns 
of an increased infection risk with these devices, no 
specific recommendation exists as to what degree of 
immunosuppression imparts a meaningful risk of infection 
in patients with SLE.[27]
Adverse Outcomes in Pregnancy
Advances in disease management, prepregnancy 
counseling, and monitoring during pregnancy have led to 
a significant improvement in pregnancy outcomes in SLE. 
The rate of pregnancy loss has decreased from 43% in 
1960–65 to 17% in 2000–03, which approximates that of 
the general US population.[28] Despite these improvements, 
however, pregnancy in SLE still carries a high risk of 
complications as shown in Table 2. Interrogation of the 
US national database of 16.7 million deliveries (2000–03) 
identified 13,555 deliveries in women with SLE and 
found an increased risk of maternal death, preeclampsia, 
preterm labor, thrombosis, infection, and hematological 
complications during SLE compared with non‑SLE 
pregnancies.[29] Notably, however, women with SLE in this 
study were older and had significantly higher rates of 
comorbidities than women in non‑SLE pregnancies.
Women with SLE are at particular risk of developing adverse 
pregnancy outcomes related to placental disease. For 
instance, they have a much higher risk (23%) of developing 
hypertensive disorders in pregnancy and (5%) intrauterine 
growth restriction (IUGR) compared with (7.8% hypertension 
and 1.6% IUGR) in otherwise healthy controls.[29,30]
A significant hypertensive complication in SLE pregnancies 
is preeclampsia, a syndrome of pregnancy defined by the 
onset of hypertension and proteinuria after 20 weeks of 
gestation. In the general population, predisposing factors 
for preeclampsia include advanced maternal age, previous 
personal or family history of preeclampsia, preexisting 
hypertension, diabetes, or obesity. In SLE, specific risk 
factors are a history of lupus nephritis, presence of aPLs, 
declining complement levels, and thrombocytopenia.[31] 
These factors may also increase the risk of fetal loss and 
other adverse pregnancy outcomes as well‑being negative 
predictors for fetal survival.[19]
Pregnancy complications of anti‑Ro and anti‑La 
antibodies
Active transplacental transfer of maternal IgG takes place 
through neonatal fragment of crystallizable component/
Fc receptors (FcRn), present on the syncytiotrophoblast, 
from 16 weeks of pregnancy onward. The active placental 
transfer of maternal anti‑Ro and/or anti‑La antibodies can 
cause congenital heart block or neonatal lupus syndromes. 
The risk of congenital heart block in an anti‑Ro/La‑positive 
mother is low at 2% but rises to 15%–20% in a mother with 
a previously affected pregnancy.[32] Cardiac manifestations 
including conduction defects, structural abnormalities, 
cardiomyopathy, and congestive cardiac failure are often 
permanent and can contribute to the fetal loss. The most 
common cardiac manifestation, however, is congenital 
heart block and given the timing of placental transfer of 
maternal anti‑Ro/La antibodies, it is important to begin 
screening for this condition with fetal cardiac ultrasound 
scan at 16–20 gestation, with repeat at 28 weeks if 
the initial 20‑week scan was normal.[33] Fetal cardiac 
ultrasound auscultation with each clinic visit is advised 
and if there is evidence of progressive heart block and 
cardiac failure in the fetus, then a decision needs to be 
taken for optimal timing for a planned delivery of a viable 
fetus or termination of the pregnancy. No interventions 
have been shown to reverse established heart block.[34] 
The use of hydroxychloroquine (HCQ), however, during 
pregnancy has been shown to significantly reduce the risk 
of recurrence of cardiac neonatal lupus in the offspring of 
anti‑Ro/La‑positive women.[35] Neonatal cutaneous lupus 
is more common that heart block and presents as a florid 
cutaneous rash that fades over the first 6 months of life 
with conservative management.
Pregnancy complications of antiphospholipid 
antibodies
The presence of aPL in pregnancy is associated with 
a significant risk of recurrent fetal loss, preeclampsia, 
Table 2: Adverse pregnancy outcomes associated with 
lupus
Preeclampsia
Preterm labor
Thrombosis
Infection
Hematological complications
Intrauterine growth restriction
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placental insufficiency, IUGR, and preterm delivery.[29,30,36] 
Further details of how patients with aPL are managed in 
pregnancy are given in an accompanying article "Pregnancy 
in antiphospholipid syndrome" on pages S117‑S121 in this 
issue.
Predictors of adverse pregnancy outcomes in 
systemic lupus erythematosus pregnancy
Various single‑center cohort studies in SLE have identified 
several novel predictors of poor pregnancy outcomes, 
such as mid‑gestational biomarkers, including ferritin, 
estradiol, and uric acid in a prospective study of n = 40 
SLE pregnancies[37] and uterine artery Doppler findings 
in a retrospective study of n = 65 SLE pregnancies.[38] 
The largest study of adverse pregnancy outcomes in SLE 
is the Predictors of Pregnancy Outcome: Biomarkers in 
Antiphospholipid Antibody Syndrome and SLE (PROMISSE) 
study. This prospective multicenter study has assessed 
the frequency of adverse pregnancy outcomes and clinical 
and laboratory variables that predict them, in women 
with aPL and/or (inactive, mild, or moderate) SLE at 
conception. To date, this study has reported that LA‑rather 
than aCL or aβ2GPI‑positivity is the primary predictor of 
adverse pregnancy outcomes in two independent groups 
of patients recruited at different time intervals, n = 144 
aPL‑positive patients recruited between 2003 and 2011[39] 
and n = 44 aPL‑positive patients recruited between 2011 
and 2015.[40] It has also shown that in n = 385 pregnant 
patients with inactive or stable mild/moderate SLE, severe 
flares are infrequent and in the absence of specific risk 
factors (LA positive, use of antihypertensive medications, 
nonwhite or Hispanic mother) pregnancy outcomes are 
favorable.[41] Although this knowledge is very useful when 
counseling patients considering lupus pregnancy, there 
are certain limitations of the PROMISSE study such as the 
timing of patient enrollment that precludes ascertainment 
of first‑trimester loss, exclusion of patients with lupus 
nephritis, and/or severe SLE disease activity. Therefore, 
further studies to include patients with more severe SLE 
are required.
Disease Flares during Pregnancy
There are conflicting results of the impact of pregnancy on 
SLE activity, with some studies reporting no increased risk 
of SLE flares during pregnancy compared with controls[42‑44] 
while others found pregnancy to be associated with 
increased SLE flares rate compared with control.[45‑47] 
Overall, many studies have identified between 35% and 
70% of all pregnancies in patients with SLE to have some 
form of measurable disease activity of which 15%–30% 
have a moderate to severe flare during pregnancy.[48] 
These discrepant findings are likely to reflect differences in 
definitions of SLE flares, assessment of disease activity, and 
selection of control group. In particular, there are certain 
physiological changes which occur in pregnancy that can 
be hard to differentiate from a lupus flare including an 
increase in proteinuria and hypertension which could lead 
to overestimation of lupus flares.
There is consensus, however, that the risk for SLE flare 
during pregnancy is increased in patients with active 
disease within 4–6 months of pregnancy,[17,18] active disease 
at conception,[44,49] a history of highly active disease in the 
years prior to pregnancy, and discontinuation of HCQ.[18,50]
Management during Pregnancy
Given the complex nature of SLE and its relationship with 
pregnancy, management of these patients should involve 
a multidisciplinary approach that considers prepregnancy 
counseling; therapy received prior to, during, and after 
pregnancy; early recognition of both obstetric and medical 
complications relating to the underlying disease; prenatal 
fetal development; and postnatal management of the 
patient and infant. Ideally, patients should be managed 
by clinicians with specialized expertise in early recognition 
and treatment of complications of pregnancy, to allow 
appropriate risk assessment/stratification of the patient, 
and provision of an individualized plan for antenatal and 
postnatal management of such high‑risk pregnancies.[51]
Treatment of SLE during pregnancy is guided by the 
degree and severity of organ involvement, similar to the 
nonpregnant state. Given the direct relationship between 
active SLE and adverse pregnancy outcomes, adequate 
control of disease activity in pregnancy is paramount. 
Various anti‑inflammatory, immunosuppressive, and/
or biologic drugs may be required to control SLE disease 
activity outside of pregnancy. The use of many of these 
drugs in pregnancy, however, is contraindicated because 
exposure increases the risk of congenital malformations 
and spontaneous abortion. Recent, British Society of 
Rheumatology (BSR) and European League Against 
Rheumatism publications have issued evidence‑based 
recommendations on prescribing antirheumatic drugs 
in pregnancy and breastfeeding.[52,53] These documents 
systematically review all current evidence on the use of 
various antirheumatic drugs before/during pregnancy 
and breastfeeding in patients with rheumatic disease. 
They provide invaluable guidance for all health‑care 
professionals to allow prescribing in SLE of drugs 
compatible with pregnancy to ensure maintenance of 
remission or treatment of disease flare. Certain drugs that 
are safe to use in SLE pregnancy are shown in Table 3.
The main principles of management of SLE before, during, 
and after pregnancy are outlined in Figure 1. Prepartum, it 
is important to ensure a period of low/no disease activity 
for more than 4 months preconception. Stop medications 
that are harmful in pregnancy, such as mycophenolate 
mofetil (MMF) and CYC. Screen for the presence of 
anti‑Ro/La and aPL and stratify risk according to the 
degree of organ involvement. In addition, it is important to 
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reassure patients that HCQ is safe throughout pregnancy 
and breastfeeding[52,53] and withdrawal of this drug may 
actually be harmful since that has been associated with 
a flare of SLE in pregnancy.[38,39] Therefore, HCQ should be 
continued in all pregnant women with SLE. A prospective 
study[54] has confirmed that patients with quiescent renal 
lupus can be safely transitioned from MMF to azathioprine 
preconception and this drug is then safe to continue 
throughout pregnancy and breastfeeding.[52]
At conception, all patients with SLE should be commenced 
on low‑dose aspirin since it has been shown to reduce the 
risk of preeclampsia in non‑SLE high‑risk pregnancies.[55] 
In patients with renal disease and/or hypertension, other 
medications which may need to be altered at this time 
include angiotensin converting enzyme inhibitors that are 
associated with a specific pattern of fetal malformation 
and should be switched to alternative antihypertensive 
drugs, such as amlodipine that are compatible with 
pregnancy.[56] Immunosuppressive drugs that may safely 
be used through pregnancy also include ciclosporin and 
tacrolimus. In addition, corticosteroids (prednisolone, 
prednisone, and methylprednisolone) are metabolized in 
the placenta, so 10% or less of the active drug reaches 
the fetus; thus they are compatible with pregnancy and 
breastfeeding.[52] Typically, disease flares are managed in 
pregnancy by reducing dose regimes of oral prednisolone 
or intravenous pulse therapy with methylprednisolone 
to minimize adverse effects of corticosteroids on 
blood glucose, blood pressure, and bone density. It is 
important to ensure calcium supplementation in all 
women with SLE in pregnancy, particularly when taking 
corticosteroids although Vitamin D supplementation 
is best preserved for women at most risk of Vitamin D 
deficiency and rickets.[57]
When dealing with patients with a possible disease flare 
in pregnancy, it is important to distinguish between 
preeclampsia and lupus nephritis flares as the management 
of these two conditions is different. This distinction 
can be difficult as both may present with increasing 
proteinuria, deteriorating renal function, hypertension, 
and thrombocytopenia. The traditional biomarkers of 
SLE activity are less helpful since C3 and C4 serum levels 
normally rise steadily during pregnancy and in patients 
with preeclampsia;[41] hence, a drop in C3 and C4 coupled 
with a rising anti‑dsDNA titer is likely to be associated with 
a disease flare in patient with SLE and proteinuria. The 
presence of active urinary sediments and signs of other 
disease activity including arthritis, cutaneous vasculitis, 
ulcers, and lymphadenopathy also point toward a lupus 
flare. Prednisolone will generally worsen preeclampsia 
but improve renal lupus. Interestingly, one SLE cohort 
study found that most patients with a relapse of nephritis 
in pregnancy were not hypertensive, in contrast to SLE 
complicated by preeclampsia patients.[16] Ultimately, a 
renal biopsy may be required to differentiate, however, 
the risk associated with this procedure often precludes its 
use in advanced pregnancy. Ultimately, delivery of a viable 
fetus may be the only definitive treatment.
Biologic therapy in SLE is centered upon B‑cell blockade 
with rituximab (RTX) or belimumab (BEL). Currently, 
however, there is insufficient evidence to recommend their 
use in pregnancy. Therefore, despite limited evidence that 
RTX is not teratogenic and only second/third‑trimester 
exposure is associated with neonatal B‑cell depletion, 
the BSR guideline concludes that RTX should be stopped 
6 months before conception although unintentional 
RTX exposure early in the first trimester is unlikely to 
be harmful.[52] Similarly, although limited data from BEL 
exposed pregnancies have not identified any harmful 
effects, the BSR guideline does not recommend BEL in 
pregnancy or breastfeeding, but unintentional exposure 
early in the first trimester is unlikely to be harmful.[52]
Table 3: Drugs safe to use in systemic lupus  
erythematosus pregnancy
Drug Recommendations
NSAIDs Use with caution in the first trimester 
‑ Possible low risk of miscarriage and 
congenital malformation. Avoid in last 
trimester ‑ Associated with premature 
close of ductus arteriosus
Corticosteroids Prednisolone and methylprednisolone 
have ≤10% placental transfer and are 
safe in all trimesters and breastfeeding
Hydroxychloroquine Safe throughout pregnancy and 
breastfeeding
Azathioprine Safe throughout pregnancy ‑ Limit dose 
to 2 mg/kg/day
Calcineurin inhibitors 
(ciclosporin and 
tacrolimus)
Safe throughout pregnancy
NSAIDs: Nonsteroidal anti‑inflammatory drugs
Pre-
conception
Pregnancy
Post partum
• Clinical review Aim for disease remission for at least 4 months
• Drugs - Ensure adequate washout of teratogenic drugs
• Antibodies - Check aPLs and anti-Ro antibodies
• Avoid pregnancy in patients with severe pulmonary
 hypertension, renal failure, previous history of stroke in last 6 months
• Clinical review:
• Dictated by disease activity/manifestations and obstetric complications 
• Check BP, urine dip, full blood count, renal/liver function, SLE biomarkers each visit
• Drugs - See Figure 3 for safe drugs in pregnancy. Hydroxychloroquine
 recommended throughout. All SLE patients on low dose Aspirin. Patients with
 thrombotic APS switch to Heparin at confirmed pregnancy. Check BP medication. 
• Antibodies -  If anti-Ro positive fetal cardiac ultrasound scan at 16-20 gestation with
 repeat at 28 weeks if the initial 20-weeks scan was normal 
• Clinical review: closely monitor for flare of lupus up to 4 months post-partum
• Drugs ensure compatibility with breast feeding
• Antibodies - For thrombotic APS patients - switch Heparin to Warfarin
Figure 1: Management of pregnancy in lupus
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Conclusion
Management of patients with SLE before, during, and 
after pregnancy is complicated by several factors including 
an increased burden of pregnancy morbidity, complex 
relationship with disease activity, and the presence of 
preexisting comorbidities requiring multiple medications 
that may be incompatible with pregnancy. Appropriate 
risk assessment/stratification, however, of each patient 
and provision of an individualized plan for antenatal and 
postnatal management will provide an optimal chance of a 
successful pregnancy outcome.
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